HUP0000386A1 - Adamantánaminok és szerkezetileg hasonló vegyületek alkalmazása borna-betegséget okozó vírus leküzdésére, valamint kedélybetegségek és más, a borna-betegséget okozó vírusfertőzéssel kapcsolatos zavarok megelőzésére és kezelésére - Google Patents
Adamantánaminok és szerkezetileg hasonló vegyületek alkalmazása borna-betegséget okozó vírus leküzdésére, valamint kedélybetegségek és más, a borna-betegséget okozó vírusfertőzéssel kapcsolatos zavarok megelőzésére és kezeléséreInfo
- Publication number
- HUP0000386A1 HUP0000386A1 HU0000386A HUP0000386A HUP0000386A1 HU P0000386 A1 HUP0000386 A1 HU P0000386A1 HU 0000386 A HU0000386 A HU 0000386A HU P0000386 A HUP0000386 A HU P0000386A HU P0000386 A1 HUP0000386 A1 HU P0000386A1
- Authority
- HU
- Hungary
- Prior art keywords
- treatment
- prevention
- disease virus
- borna disease
- combating
- Prior art date
Links
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 title abstract 4
- 241000724653 Borna disease virus Species 0.000 title abstract 4
- 208000015181 infectious disease Diseases 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 208000035475 disorder Diseases 0.000 title abstract 2
- 208000017194 Affective disease Diseases 0.000 title 1
- -1 adamantane amines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 229940052761 dopaminergic adamantane derivative Drugs 0.000 abstract 3
- 208000019022 Mood disease Diseases 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 241000776207 Bornaviridae Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Adamantánaminok és szerkezeti analógjaik alkalmazása emberen ésállaton a Bornaviridae családhoz tartozó vírusok, különösen a Borna-betegség vírusának leküzdésére. Az adamantánszármazékok in vivokörülmények között igen jó hatással alkalmazhatók kedélybetegségek,valamint BDV-fertőzésekkel kapcsolatos zavarok megelőzésére éskezelésére, így a Borna-betegség vírusával előidézett fertőzésekkelkapcsolatos kedélybetegségek, például depresszió megelőzésére éskezelésére. Adamantánszármazékokként elsősorban 1-amino-, 1-(alkil-amino)- vagy 1-(amino-alkil)-csoporttal szubsztituáltadamantánszármazékok és ezek gyógyászati szempontból elfogadható sóivehetők számításba. A találmány szerinti kezelés a vírus aktivitásátmegszünteti. Jelentős mellékhatásokkal nem kell számolni. Ó
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19644998A DE19644998C1 (de) | 1996-10-30 | 1996-10-30 | Verwendung von Adamantanaminen oder strukturanaloger Verbindungen zur Bekämpfung von Borna Disease Virus und zur Prophylaxe und Behandlung von Affekterkrankungen und anderen mit BDV-Infektionen verbundenen Störungen bei Mensch und Tier |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0000386A1 true HUP0000386A1 (hu) | 2000-12-28 |
HUP0000386A3 HUP0000386A3 (en) | 2001-04-28 |
Family
ID=7810348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0000386A HUP0000386A3 (en) | 1996-10-30 | 1997-10-23 | Use of adamantane amines or structurally similar compounds for combating borna disease virus and for the prevention and treatment of affective diseases and other disorders associated with bdv infections |
Country Status (16)
Country | Link |
---|---|
US (1) | US6384083B1 (hu) |
EP (1) | EP0935461B1 (hu) |
JP (1) | JP4290764B2 (hu) |
CN (1) | CN1133425C (hu) |
AT (1) | ATE245975T1 (hu) |
AU (1) | AU722505B2 (hu) |
BR (1) | BR9712466A (hu) |
CA (1) | CA2306830C (hu) |
CZ (1) | CZ148999A3 (hu) |
DE (2) | DE19644998C1 (hu) |
DK (1) | DK0935461T3 (hu) |
ES (1) | ES2207751T3 (hu) |
HU (1) | HUP0000386A3 (hu) |
IL (1) | IL129612A (hu) |
PL (1) | PL189608B1 (hu) |
WO (1) | WO1998018457A1 (hu) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10066158B4 (de) * | 2000-08-24 | 2007-08-09 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms |
DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
EP1638931A4 (en) * | 2003-06-11 | 2007-11-07 | Neuromolecular Inc | METHOD FOR TARGETING A THERAPEUTIC AGENT |
UY28650A1 (es) * | 2003-12-05 | 2005-02-28 | Forest Laboratories | Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta |
US8058291B2 (en) * | 2005-04-06 | 2011-11-15 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of CNS-related conditions |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
CA2588296A1 (en) | 2004-11-24 | 2006-06-01 | Neuromolecular Pharmaceuticals, Inc. | Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease |
US8393169B2 (en) | 2007-09-19 | 2013-03-12 | Emerson Climate Technologies, Inc. | Refrigeration monitoring system and method |
MX365650B (es) | 2009-12-02 | 2019-06-10 | Adamas Pharmaceuticals Inc | Composiciones de amantadina y metodos para su uso. |
CN102241678B (zh) | 2011-04-26 | 2014-10-29 | 辽宁利锋科技开发有限公司 | 含有脂环结构化合物的抗肿瘤作用与应用 |
US8835507B2 (en) * | 2012-02-21 | 2014-09-16 | Vymed Corporation | Adamantane derivatives possessing anti-viral and anti-microbial activity |
WO2014204933A1 (en) | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
DE102018009721A1 (de) * | 2017-12-29 | 2019-07-04 | Euroimmun Medizinische Labordiagnostika Ag | Verfahren zur Diagnose einer Bornavirus-Infektion |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR6482M (hu) * | 1916-09-20 | 1968-11-25 | ||
DE2224539A1 (de) * | 1972-05-19 | 1973-12-06 | Merz & Co | Aminoadamantanverbindungen und verfahren zu ihrer herstellung |
US4174407A (en) * | 1978-01-13 | 1979-11-13 | Sumitomo Chemical Company, Limited | Antiviral agent |
US4148896A (en) * | 1978-02-22 | 1979-04-10 | E. I. Du Pont De Nemours And Company | Antidepressant combination |
US4174047A (en) * | 1978-03-06 | 1979-11-13 | 3-in-1, Inc. | Vending machine for newspapers and the like |
DE3921062A1 (de) * | 1989-06-23 | 1991-01-03 | Lange Werner | Therapie und prophylaxe von infektionen mit retroviren mit 1-adamantanamin hydrochlorid (amantadin) allein oder in kombination mit anderen antiviralen substanzen |
DE4014672A1 (de) * | 1990-05-08 | 1991-11-14 | Werner E G Prof Dr Mueller | Verwendung von adamantan-derivaten zur zytoprotektion von nicht-infizierten und virus-infizierten lymphozyten als auch anderen zelltypen |
WO1992017168A1 (en) * | 1991-04-04 | 1992-10-15 | The Children's Medical Center Corporation | Method of preventing nmda receptor-mediated neuronal damage |
US5576355A (en) * | 1993-06-04 | 1996-11-19 | Mobil Oil Corp. | Diamondoid derivatives for pharmaceutical use |
DE19510189A1 (de) * | 1995-03-21 | 1996-09-26 | Hartmut Dr Goebel | Verwendung von Amantadin |
-
1996
- 1996-10-30 DE DE19644998A patent/DE19644998C1/de not_active Expired - Fee Related
-
1997
- 1997-10-23 ES ES97945778T patent/ES2207751T3/es not_active Expired - Lifetime
- 1997-10-23 WO PCT/DE1997/002455 patent/WO1998018457A1/de not_active Application Discontinuation
- 1997-10-23 CN CNB971993416A patent/CN1133425C/zh not_active Expired - Lifetime
- 1997-10-23 HU HU0000386A patent/HUP0000386A3/hu unknown
- 1997-10-23 US US09/297,489 patent/US6384083B1/en not_active Expired - Lifetime
- 1997-10-23 CZ CZ991489A patent/CZ148999A3/cs unknown
- 1997-10-23 DE DE59710517T patent/DE59710517D1/de not_active Expired - Lifetime
- 1997-10-23 CA CA002306830A patent/CA2306830C/en not_active Expired - Fee Related
- 1997-10-23 PL PL97333059A patent/PL189608B1/pl not_active IP Right Cessation
- 1997-10-23 AU AU51162/98A patent/AU722505B2/en not_active Ceased
- 1997-10-23 BR BR9712466-4A patent/BR9712466A/pt not_active IP Right Cessation
- 1997-10-23 JP JP51988498A patent/JP4290764B2/ja not_active Expired - Lifetime
- 1997-10-23 IL IL12961297A patent/IL129612A/xx not_active IP Right Cessation
- 1997-10-23 EP EP97945778A patent/EP0935461B1/de not_active Expired - Lifetime
- 1997-10-23 AT AT97945778T patent/ATE245975T1/de not_active IP Right Cessation
- 1997-10-23 DK DK97945778T patent/DK0935461T3/da active
Also Published As
Publication number | Publication date |
---|---|
US6384083B1 (en) | 2002-05-07 |
EP0935461B1 (de) | 2003-07-30 |
JP2001502701A (ja) | 2001-02-27 |
DE59710517D1 (de) | 2003-09-04 |
WO1998018457A1 (de) | 1998-05-07 |
ATE245975T1 (de) | 2003-08-15 |
AU5116298A (en) | 1998-05-22 |
DE19644998C1 (de) | 1998-06-10 |
HUP0000386A3 (en) | 2001-04-28 |
BR9712466A (pt) | 1999-12-21 |
IL129612A (en) | 2003-02-12 |
ES2207751T3 (es) | 2004-06-01 |
CA2306830A1 (en) | 1998-05-07 |
PL333059A1 (en) | 1999-11-08 |
DK0935461T3 (da) | 2003-11-24 |
CN1235540A (zh) | 1999-11-17 |
CZ148999A3 (cs) | 1999-11-17 |
EP0935461A1 (de) | 1999-08-18 |
AU722505B2 (en) | 2000-08-03 |
PL189608B1 (pl) | 2005-08-31 |
IL129612A0 (en) | 2000-02-29 |
CN1133425C (zh) | 2004-01-07 |
CA2306830C (en) | 2008-07-08 |
JP4290764B2 (ja) | 2009-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0000386A1 (hu) | Adamantánaminok és szerkezetileg hasonló vegyületek alkalmazása borna-betegséget okozó vírus leküzdésére, valamint kedélybetegségek és más, a borna-betegséget okozó vírusfertőzéssel kapcsolatos zavarok megelőzésére és kezelésére | |
DE69920757D1 (de) | Immunsuppressive wirkungen von pteridinderivaten | |
HUP0204459A2 (en) | Method for the improvement of islet signaling in diabetes mellitus and for its prevention | |
EA199901031A1 (ru) | Производные бензимидазола | |
NO961326L (no) | Inhibitorer av -amyloidproteinproduksjon | |
HK1057899A1 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
EA200100524A1 (ru) | Амиды антраниловой кислоты и их применение в качестве лекарственных средств | |
RU93058531A (ru) | Фторалкоксибензиламинные производные азотсодержащих гетероциклов, фармацевтическая композиция, способ лечения | |
DK1140139T3 (da) | Anvendelse af erythropoietin eller erythropoietinderivater til behandling af cerebrale iskræmier | |
HK1087702A1 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
EA200100127A1 (ru) | Производные фенилксантина | |
NO20052272L (no) | CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom | |
WO2005067900A3 (en) | Azabenzofuran substituted thioureas as inhibitors of viral replication | |
ES2061727T3 (es) | Sustancias fisiologicamente activas, un procedimiento para su preparacion y composiciones farmaceuticas que las contienen. | |
ES2063998T3 (es) | Uso de esteres de acidos n-alquil 1,4-dihidropiridin-dicarboxilicos como medicamentos, nuevos compuestos y procedimiento para su preparacion. | |
HUP0100611A2 (hu) | Triazin vegyületek, és ilyeneket tartalmazó gyógyszerkészítmények a központi idegrendszer elváltozásainak kezelésére | |
EP0615750A2 (en) | Treatment of a group of related disorders | |
CO5690571A2 (es) | Combinacion sinergica que comprende roflumilas y (r,r)-formoterol | |
MC1930A1 (fr) | Produit antiviral | |
UY27372A1 (es) | Derivados de bencimidazol 1-aril-2-n, s u o-sustituidos, su uso para la obtención de medicamentos y preparados farmacéuticos que contienen estos derivados | |
NO20056089L (no) | Glykosaminoglykaner for behandling av emosjonelle dysfunksjoner | |
HUP9701284A2 (hu) | 2,3-Benzodiazepin-származékok felhasználása az endogén opioid rendszerrel összefüggő betegségek és állapotok kezelésére, és megelőzésére alkalmas gyógyászati készítmények előállítására | |
RU94016333A (ru) | Лекарственное средство для лечения вирусных заболеваний | |
HUP0200148A2 (hu) | N-(3',4'-dimetoxi-cinnamoil)antranilsav alkalmazása szívkoszorúér-műtéttel kapcsolatos cardiovascularis események megelőzésére vagy mérséklésére | |
YU36499A (sh) | Primena 1-/4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropirid -1-il/2-(6,7-dimetoksinaft-2-il)etana za dobijanje medikamenata za neurotrofno dejstvo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |